Tweets
Phase 3 Study of IV Secukinumab for treatment of PsA - efficacious and safety profile similar to Subq version
~60% ACR 50 response maintained at week 52
2nd responses of MDA, PASI90, enthesitis, dactylitis resolution met
@RheumNow #ACR23 Abs#0776 https://t.co/jikWd4fnGm
Robert B Chao, MD ( View Tweet )
2 years 3 months ago
Entrevista de @RheumNow a las doctoras Griselda Serna Peña y Diana Flores Gutierrez sobre su trabajo de Screening y salud secual en pacientes con enfermedades reumáticas
#ACR23 @SernaDra @ColMexReuma https://t.co/SyuFVXM9Sf
ReumaJoven ( View Tweet )
2 years 3 months ago
RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow and its faculty
Dr. John Cush @RheumNow ( View Tweet )
2 years 3 months ago
Reporting for @RheumNow! #ACR23 follow our coverage! @ACRheum @uptotate @Yuz6Yusof @ericdeinmd https://t.co/e4ShTzZhrE
TheDaoIndex @KDAO2011 ( View Tweet )
2 years 3 months ago
Upadacitinib on wearable device-measure activity
SELECT-AXIS 2
Abs#0530 #ACR23 @RheumNow
UPA had numerically higher mean daily step counts than PBO
11% improvement v PBO at wk 14 (diff of 345 steps/day)
Sedentary pts: 22% improvement in daily step count from b/l on UPA (4% PBO) https://t.co/Gq91TmvfZC
Eric Dein ( View Tweet )
2 years 3 months ago
What are effects of TNFi on Lipids in AxSpA?
Ab#0531 #ACR23 @RheumNow
320 pts w AS - retrosp cohort, first-line TNFi, not on lipid Rx
Chol and TG increase in 1st 3 mos of treatment. LDL & HDL: no signif change
Inflam markers/Lipids correlated - suspect due to anti-inflamm effect https://t.co/qT5qUEOEvO
Eric Dein ( View Tweet )
2 years 3 months ago
Is exercise safe in PsO/PsA? Ab0497 #ACR23
US of entheses before & after 60 min of badminton 🏸
7 PsA pts, 9 PsO pts, 196 US scans acquired.
No signif change in VAS pain/tender entheses
4 pts w grade 1 doppler at 6 entheses, butnon-tender
1 pt w active PsA had worsening
@RheumNow https://t.co/nsi9b6px0X
Eric Dein ( View Tweet )
2 years 3 months ago
Translational implication/application of the #APOL1 story :
Risk stratification, novel treatments, impact of tissue susceptibility to damage #ACR23 @RheumNow #DuboisLecture #SLE @ashira_md https://t.co/k23vFjeDeG
TheDaoIndex @KDAO2011 ( View Tweet )
2 years 3 months ago
Ab#498 Does DMARD for PsO and PsA decrease MACE?
#ACR23 @RheumNow
Retrospective database Israeli study.
PsO, PsA on MTX or bDMARD: lower MACE compared to health matched controled (HR 0.45-0.68, p<0.001)
Pts on topical Rx had marginally Increased MACE (HR 1.14, p <0.001) https://t.co/0uRgjzYbFp
Eric Dein ( View Tweet )
2 years 3 months ago
BKZ tx resulted in sustained improvements in pt‑reported pain and fatigue from Wk 16 - 52 in bDMARD-naïve and TNFi-IR pts w/ active PsA, w/ clinically meaningful improvements observed in >50% of pts in BE-OPTIMAL & BE-COMPLETE #ACR23 Abs 0527 https://t.co/AQKYUubKLl @rheumnow https://t.co/WsXlhENzL1
Dr. Rachel Tate ( View Tweet )
2 years 3 months ago
Abs#0501 @RheumNow #ACR23
Uveitis in SpA, from Greece
AxSpA: 11.7% Uveitis. RF: HLA-B27 (OR 4.15), periperhal arthritis (OR 3.05)
PsA: 2.7% Uveitis. Ass w/ SpA FHx, Axial dis at dx, disease duration
Permanent vision loss in 16% AxSpA, 30% PsA pts, all with recurrent uveitis
Eric Dein ( View Tweet )
2 years 3 months ago
EISER study: Undiagnosed IBD in SpA
Abs#0495 #ACR23 @RheumNow
559 pts, 47% PsA/53% SpA (80% r-AxSpA)
Higher mean fecal calprotectin in r-AxSpA (395 vs 305 nrAxSpA/PsA)
14.6% IBD symptoms, 23 patients (4.4% were dx w IBD)
Fecal calprotectin & history can uncover IBD
#ACRBest
Eric Dein ( View Tweet )
2 years 3 months ago
